Clinical Trials Browser

Phase 2 × OTHER × Resectable Stage IIA to IIIB Non-small Cell Lung Cancer × Clear all

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer